<p>Kodiak Sciences Inc.（纳斯达克代码：KOD - 获取免费报告）在周一交易前因内部人士购买活动而股价跳涨。该股票此前收于 26.00 美元，但开盘价为 27.95 美元。Kodiak Sciences 的股票最后交易价格为 28.2410 美元，成交量为 141,605 股。</p>
<p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<p>具体来说，董事 Bros. Advisors Lp Baker 在 12 月 18 日（星期四）的一笔交易中购买了 2,608,696 股该股票。这些股票的平均购买价格为每股 23.00 美元，总价值为 60,000,008.00 美元。收购后，该董事直接持有公司 18,358,772 股股票，价值 422,251,756 美元。这代表其持股比例增加了 16.56%。该交易已在与 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
<h2>分析师设定新目标价</h2>
<p>几家券商对 KOD 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对 Kodiak Sciences 股票的 “卖出（e+）” 评级。Lifesci Capital 在 10 月 23 日（星期四）的一份研究报告中开始覆盖 Kodiak Sciences 股票。他们给予该公司的 “跑赢大盘” 评级，并设定了 40.00 美元的目标价。摩根大通在 10 月 24 日（星期五）的一份研究报告中将 Kodiak Sciences 的评级从 “中性” 上调至 “增持”，并将其目标价从 15.00 美元提高至 24.00 美元。Chardan Capital 在 11 月 17 日（星期一）的一份研究报告中重申了 “中性” 评级，并设定了 14.00 美元的目标价。最后，华尔街 Zen 在 10 月 11 日（星期六）的一份报告中将 Kodiak Sciences 的评级从 “持有” 下调至 “卖出”。四位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 22.67 美元。</p>
<p><strong>查看我们对 KOD 的最新分析</strong></p>
<h2>Kodiak Sciences 股票表现</h2>
<p>该公司的市值为 14.6 亿美元，市盈率为-6.85，贝塔值为 2.68。该公司的 50 日移动平均线为 20.38 美元，200 日移动平均线为 12.43 美元。</p>
<p>Kodiak Sciences（纳斯达克代码：KOD - 获取免费报告）最后一次发布财报是在 11 月 13 日（星期四）。该公司报告的每股收益为（1.16 美元），低于分析师的共识预期（1.07 美元）0.09 美元。股票分析师预计 Kodiak Sciences Inc.在当前财政年度将发布-3.45 的每股收益。</p>
<h2>Kodiak Sciences 的机构交易</h2>
<p>几家对冲基金和其他机构投资者最近买卖了该股票的股份。Headlands Technologies LLC 在第二季度将其在 Kodiak Sciences 的持股比例提高了 256.4%。Headlands Technologies LLC 现在拥有 8,083 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 5,815 股。Walleye Capital LLC 在第一季度收购了 Kodiak Sciences 的新股份，价值约 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Kodiak Sciences 的持股比例提高了 21.7%。Vanguard Personalized Indexing Management LLC 现在拥有 15,070 股该公司的股票，价值 56,000 美元，此前在此期间又购买了 2,691 股。Russell Investments Group Ltd.在第一季度将其在 Kodiak Sciences 的持股比例提高了 729.9%。Russell Investments Group Ltd.现在拥有 21,039 股该公司的股票，价值 59,000 美元，此前在上个季度又收购了 18,504 股。最后，Dynamic Technology Lab Private Ltd 在第一季度收购了 Kodiak Sciences 的新股份，价值 94,000 美元。89.06% 的股票由机构投资者和对冲基金持有。</p>
<h2>Kodiak Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Kodiak Sciences, Inc 是一家总部位于加利福尼亚州帕洛阿尔托的临床阶段生物制药公司，专注于新型视网膜疾病疗法的发现和开发。该公司的专有技术集中在抗体生物聚合物结合物（ABCs）上，旨在延长耐久性、增强组织渗透性并改善现有治疗方式的安全性。Kodiak 的研发工作针对湿性年龄相关性黄斑变性（湿性 AMD）、糖尿病性黄斑水肿（DME）和其他严重眼科疾病。</p>
<p>Kodiak 研发管道中的主要产品候选是 KSI-301，一种通过玻璃体内注射给药的抗 VEGF 抗体生物聚合物结合物。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比 Kodiak Sciences 更好</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>“客户银行存款 660 亿美元面临风险”</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Kodiak Sciences 吗？</h2>
<p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Kodiak Sciences 并不在名单上。</p>
<p>虽然 Kodiak Sciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Kodiak Sciences（纳斯达克代码：KOD）股价因内部人士买入活动而上涨。董事会顾问公司 Bros. Advisors Lp 的 Baker 以每股 23.00 美元购买了 2,608,696 股，总计 6000 万美元。该股票开盘价为 27.95 美元，较前一交易日的 26.00 美元上涨，最后交易价为 28.2410 美元。分析师对该股票的评级不一，普遍评级为 “持有”，目标价为 22.67 美元。Kodiak Sciences 专注于视网膜疾病的治疗，其主要产品候选药物为 KSI-301</p>

<p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $26.00, but opened at $27.95. Kodiak Sciences shares last traded at $28.2410, with a volume of 141,605 shares trading hands.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc.（纳斯达克代码：KOD - 获取免费报告）在周一交易前因内部人士购买活动而股价跳涨。该股票此前收于 26.00 美元，但开盘价为 27.95 美元。Kodiak Sciences 的股票最后交易价格为 28.2410 美元，成交量为 141,605 股。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><p>Specifically, Director Bros. Advisors Lp Baker bought 2,608,696 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $23.00 per share, with a total value of $60,000,008.00. Following the acquisition, the director directly owned 18,358,772 shares of the company's stock, valued at $422,251,756. This represents a 16.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>具体来说，董事 Bros. Advisors Lp Baker 在 12 月 18 日（星期四）的一笔交易中购买了 2,608,696 股该股票。这些股票的平均购买价格为每股 23.00 美元，总价值为 60,000,008.00 美元。收购后，该董事直接持有公司 18,358,772 股股票，价值 422,251,756 美元。这代表其持股比例增加了 16.56%。该交易已在与 SEC 的法律文件中披露，相关信息可通过 SEC 网站访问。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several brokerages have issued reports on KOD. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Lifesci Capital initiated coverage on shares of Kodiak Sciences in a research report on Thursday, October 23rd. They issued an &#34;outperform&#34; rating and a $40.00 target price for the company. JPMorgan Chase &amp; Co. raised Kodiak Sciences from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and increased their price target for the company from $15.00 to $24.00 in a research report on Friday, October 24th. Chardan Capital restated a &#34;neutral&#34; rating and set a $14.00 target price on shares of Kodiak Sciences in a research report on Monday, November 17th. Finally, Wall Street Zen downgraded Kodiak Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, October 11th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $22.67.</p>
<div class="lb-trans"><p>几家券商对 KOD 发布了报告。Weiss Ratings 在 10 月 8 日（星期三）的一份研究报告中重申了对 Kodiak Sciences 股票的 “卖出（e+）” 评级。Lifesci Capital 在 10 月 23 日（星期四）的一份研究报告中开始覆盖 Kodiak Sciences 股票。他们给予该公司的 “跑赢大盘” 评级，并设定了 40.00 美元的目标价。摩根大通在 10 月 24 日（星期五）的一份研究报告中将 Kodiak Sciences 的评级从 “中性” 上调至 “增持”，并将其目标价从 15.00 美元提高至 24.00 美元。Chardan Capital 在 11 月 17 日（星期一）的一份研究报告中重申了 “中性” 评级，并设定了 14.00 美元的目标价。最后，华尔街 Zen 在 10 月 11 日（星期六）的一份报告中将 Kodiak Sciences 的评级从 “持有” 下调至 “卖出”。四位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 22.67 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on KOD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 KOD 的最新分析</strong></p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表现</h2>
</div><p>The company has a market cap of $1.46 billion, a price-to-earnings ratio of -6.85 and a beta of 2.68. The company has a fifty day moving average of $20.38 and a two-hundred day moving average of $12.43.</p>
<div class="lb-trans"><p>该公司的市值为 14.6 亿美元，市盈率为-6.85，贝塔值为 2.68。该公司的 50 日移动平均线为 20.38 美元，200 日移动平均线为 12.43 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09). Equities analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kodiak Sciences（纳斯达克代码：KOD - 获取免费报告）最后一次发布财报是在 11 月 13 日（星期四）。该公司报告的每股收益为（1.16 美元），低于分析师的共识预期（1.07 美元）0.09 美元。股票分析师预计 Kodiak Sciences Inc.在当前财政年度将发布-3.45 的每股收益。</p>
</div><h2>Institutional Trading of Kodiak Sciences</h2>
<div class="lb-trans"><h2>Kodiak Sciences 的机构交易</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC boosted its position in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $49,000. Vanguard Personalized Indexing Management LLC lifted its holdings in Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Kodiak Sciences by 729.9% in the 1st quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after acquiring an additional 18,504 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Kodiak Sciences during the first quarter valued at $94,000. 89.06% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近买卖了该股票的股份。Headlands Technologies LLC 在第二季度将其在 Kodiak Sciences 的持股比例提高了 256.4%。Headlands Technologies LLC 现在拥有 8,083 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 5,815 股。Walleye Capital LLC 在第一季度收购了 Kodiak Sciences 的新股份，价值约 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Kodiak Sciences 的持股比例提高了 21.7%。Vanguard Personalized Indexing Management LLC 现在拥有 15,070 股该公司的股票，价值 56,000 美元，此前在此期间又购买了 2,691 股。Russell Investments Group Ltd.在第一季度将其在 Kodiak Sciences 的持股比例提高了 729.9%。Russell Investments Group Ltd.现在拥有 21,039 股该公司的股票，价值 59,000 美元，此前在上个季度又收购了 18,504 股。最后，Dynamic Technology Lab Private Ltd 在第一季度收购了 Kodiak Sciences 的新股份，价值 94,000 美元。89.06% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Kodiak Sciences Company Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.</p>
<div class="lb-trans"><p>Kodiak Sciences, Inc 是一家总部位于加利福尼亚州帕洛阿尔托的临床阶段生物制药公司，专注于新型视网膜疾病疗法的发现和开发。该公司的专有技术集中在抗体生物聚合物结合物（ABCs）上，旨在延长耐久性、增强组织渗透性并改善现有治疗方式的安全性。Kodiak 的研发工作针对湿性年龄相关性黄斑变性（湿性 AMD）、糖尿病性黄斑水肿（DME）和其他严重眼科疾病。</p>
</div><p>The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.</p>
<div class="lb-trans"><p>Kodiak 研发管道中的主要产品候选是 KSI-301，一种通过玻璃体内注射给药的抗 VEGF 抗体生物聚合物结合物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Kodiak Sciences 更好</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>在 2026 年 1 月 1 日之前购买这只 2 美元的黄金股票</li>
<li>“客户银行存款 660 亿美元面临风险”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Kodiak Sciences 吗？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Kodiak Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Kodiak Sciences 并不在名单上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kodiak Sciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kodiak Sciences (NASDAQ:KOD) 的股价在内部人士买入活动后出现跳空上涨